KR100607923B1 - 증가된 용해 속도를 나타내는 결정형 에플레레논 - Google Patents

증가된 용해 속도를 나타내는 결정형 에플레레논 Download PDF

Info

Publication number
KR100607923B1
KR100607923B1 KR1020017010043A KR20017010043A KR100607923B1 KR 100607923 B1 KR100607923 B1 KR 100607923B1 KR 1020017010043 A KR1020017010043 A KR 1020017010043A KR 20017010043 A KR20017010043 A KR 20017010043A KR 100607923 B1 KR100607923 B1 KR 100607923B1
Authority
KR
South Korea
Prior art keywords
eplerenone
crystalline
solvate
composition
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017010043A
Other languages
English (en)
Korean (ko)
Other versions
KR20010112261A (ko
Inventor
바톤캐슬린
보샤트토마스비
캐로스말론브이
데사이수브하쉬
페로레오나드제이
고드헨리티
갠서스코트
리틀클레이알
무디팔리파르타에스
피에츠마크에이
필리파우스카스다니엘알
싱유엔-룽엘
스타흘글렌엘
위엑조레크요셉제이
얀크리스와이
Original Assignee
파마시아 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파마시아 코포레이션 filed Critical 파마시아 코포레이션
Publication of KR20010112261A publication Critical patent/KR20010112261A/ko
Application granted granted Critical
Publication of KR100607923B1 publication Critical patent/KR100607923B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
KR1020017010043A 1999-12-08 2000-12-04 증가된 용해 속도를 나타내는 결정형 에플레레논 Expired - Fee Related KR100607923B1 (ko)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US16968299P 1999-12-08 1999-12-08
US16960899P 1999-12-08 1999-12-08
US16955699P 1999-12-08 1999-12-08
US16963999P 1999-12-08 1999-12-08
US16969099P 1999-12-08 1999-12-08
US16980799P 1999-12-08 1999-12-08
US60/169,556 1999-12-08
US60/169,608 1999-12-08
US60/169,639 1999-12-08
US60/169,682 1999-12-08
US60/169,690 1999-12-08
US60/169,807 1999-12-08

Publications (2)

Publication Number Publication Date
KR20010112261A KR20010112261A (ko) 2001-12-20
KR100607923B1 true KR100607923B1 (ko) 2006-08-04

Family

ID=27558585

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017010043A Expired - Fee Related KR100607923B1 (ko) 1999-12-08 2000-12-04 증가된 용해 속도를 나타내는 결정형 에플레레논

Country Status (17)

Country Link
EP (1) EP1177204A2 (https=)
JP (1) JP2003516414A (https=)
KR (1) KR100607923B1 (https=)
CN (2) CN1152886C (https=)
AU (1) AU784946B2 (https=)
BR (1) BR0008057A (https=)
CA (1) CA2362669A1 (https=)
CO (1) CO5280211A1 (https=)
EA (1) EA007934B1 (https=)
HU (1) HUP0203032A3 (https=)
IL (3) IL144764A0 (https=)
MX (1) MXPA01008056A (https=)
MY (1) MY131878A (https=)
NO (1) NO20013856L (https=)
NZ (2) NZ513961A (https=)
PE (1) PE20010917A1 (https=)
WO (1) WO2001042272A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487540A2 (en) * 2002-03-20 2004-12-22 Pharmacia Corporation Storage stable eplerenone formulation
US7235655B2 (en) 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
CA2582496A1 (en) 2007-03-20 2008-09-20 Apotex Pharmachem Inc. Improved process for the preparation and purification of eplerenone
EP2977084B1 (en) 2010-05-10 2017-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
JP6180930B2 (ja) 2010-06-16 2017-08-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 創傷治癒過程における再上皮化を刺激するための方法及び組成物
JP6835836B2 (ja) 2015-10-13 2021-02-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 脈絡膜血管新生の処置のための方法及び医薬組成物
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
CN108059648A (zh) * 2017-12-30 2018-05-22 合肥久诺医药科技有限公司 一种依普利酮溶剂合物及其制备方法
US20240366632A1 (en) 2021-08-31 2024-11-07 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of ocular rosacea
WO2023204729A1 (ru) * 2022-04-19 2023-10-26 Общество с ограниченной ответственностью "Гелеспон" Фармацевтические композиции на основе новой субстанции 4-[2-(1н-имидазол-4-ил)-этилкарбамоил]-бутановой кислоты и способ получения субстанции
CN120754115A (zh) * 2025-05-23 2025-10-10 远大医药（中国）有限公司 一种含依普利酮组合物及其药物制剂、制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
WO1998025948A2 (en) * 1996-12-11 1998-06-18 G.D. Searle & Co. Processes for preparation of 9,11-epoxy steroids and intermediates useful therein
DE60005159T2 (de) * 1999-03-05 2004-07-22 G.D. Searle Llc, Chicago Kombinationstherapie von angiotensin-konvertierendem enzym hemmer und epoxy-steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen

Also Published As

Publication number Publication date
HUP0203032A2 (hu) 2002-12-28
EA007934B1 (ru) 2007-02-27
CN1557833A (zh) 2004-12-29
CN1377365A (zh) 2002-10-30
MXPA01008056A (es) 2003-07-21
EP1177204A2 (en) 2002-02-06
AU784946B2 (en) 2006-08-03
HUP0203032A3 (en) 2003-04-28
PE20010917A1 (es) 2001-09-10
CN1152886C (zh) 2004-06-09
MY131878A (en) 2007-09-28
NZ513961A (en) 2004-02-27
EA200100871A1 (ru) 2002-04-25
NO20013856L (no) 2001-10-08
WO2001042272A2 (en) 2001-06-14
WO2001042272A3 (en) 2001-11-29
WO2001042272A9 (en) 2002-12-12
CO5280211A1 (es) 2003-05-30
NO20013856D0 (no) 2001-08-08
IL144764A (en) 2007-08-19
BR0008057A (pt) 2002-04-23
NZ530028A (en) 2005-08-26
IL144764A0 (en) 2002-06-30
IL176511A (en) 2007-08-19
JP2003516414A (ja) 2003-05-13
CA2362669A1 (en) 2001-06-14
KR20010112261A (ko) 2001-12-20
AU2049201A (en) 2001-06-18
HK1050536A1 (en) 2003-06-27

Similar Documents

Publication Publication Date Title
US20090149431A1 (en) Eplerenone Drug Substance Having High Phase Purity
KR100607923B1 (ko) 증가된 용해 속도를 나타내는 결정형 에플레레논
MXPA06004489A (es) Formulacion y metodo de aripiprazol inyectable esteril de liberacion controlada.
US20050267302A1 (en) Eplerenone crystalline form exhibiting enhanced dissolution rate
US20020045746A1 (en) Eplerenone crystalline form
US20020038021A1 (en) Eplerenone crystalline form exhibiting enhanced dissolution rate
US20050159594A1 (en) Eplerenone crystal form exhibiting enhanced dissolution rate
AU2004242560B2 (en) Eplerenone crystalline form
CN105384730A (zh) 依帕列净的晶型及其制备方法、药物组合物和用途
EP1580193A2 (en) Eplerenone crystalline form
US20030083493A1 (en) Eplerenone drug substance having high phase purity
EP1505072A2 (en) Eplerenone crystalline form exhiniting enhanced dissolution rate
TWI286141B (en) Eplerenone crystal form
TWI290558B (en) Eplerenone crystalline form exhibiting enhanced dissolution rate
NZ540941A (en) Process for producing amorphous form of eplerenone exhibiting enhanced dissolution rate
MXPA01008057A (en) Eplerenone crystalline form
HK1057220B (en) Eplerenone crystalline form
HK1125841A (en) Eplerenone crystalline form
US20140056977A1 (en) Solid pharmaceutical composition containing 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (c)chromen-3-yl sulfamate and polymorphs thereof
CN101317848A (zh) 依匹乐酮晶形

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20100630

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20110727

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20110727

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000